All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2011-004651-40 | A multi-center, open label, uncontrolled, Phase IIa clinical trial evaluating the safety and efficacy of NOX-A12 in combination with a background therapy of bortezomib and dexamethasone (VD) in previo... | 2015-09-30 | due-trials |
| Reported results | 2011-004672-11 | A multi-centre, open label, uncontrolled, Phase IIa clinical trial evaluating the safety and efficacy of NOX-A12 in combination with a background therapy of bendamustine and rituximab (BR) in previous... | 2017-04-27 | due-trials |
| Reported results | 2011-005710-11 | A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuria. | 2013-12-03 | due-trials |
| Reported results | 2012-001525-27 | Phase IIa study to characterize the effects of the Spiegelmer® NOX H94 on anemia of chronic disease in patients with cancer | 2013-12-30 | due-trials |
| Reported results | 2013-003585-14 | Safety, PK/PD and efficacy of NOX-H94 in dialysis patients with ESA-hyporesponsive anaemia: A randomized, double blind, placebo controlled parallel group study with a single blind cross-over group | 2015-11-16 | due-trials |
| Exempt, with results | 2016-003657-15 | A Two-Part, Open-Label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in M... | 2020-03-25 | not-yet-due |